drugset / Trial / NCT01597531

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531

Phase 4 Terminated 1 enrolled East Carolina University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether addition of 1 or 2 medicines after gastric banding can improve remission of type 2 diabetes.

Timeline

Start
2012-06
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg Subcutaneous
Comparator Orlistat Small molecule 60 mg Oral